Oncolytics Biotech Inc. - Common Stock — 현금 흐름 (NASDAQ:ONCY)

Financials

영업활동으로 인한 현금 —————-20.11 M — 투자 활동으로 인한 현금 —————-6 000 — 재무활동으로 인한 현금 —————14.12 M — 잉여 현금 흐름 —————-20.12 M —

Oncolytics Biotech Inc. - Common Stock

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

ONCY

Financials

Oncolytics Biotech Inc. - Common Stock

뉴스

Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths (NASDAQ:ONCY)

Oncolytics launches phase 2 colorectal cancer study REO 033

Oncolytics to wind down GOBLET study, focus on U.S. registration

온콜리틱스 바이오테크, FDA 패스트트랙 지정 후 주가 급등

Oncolytics Biotech stock soars after FDA grants Fast Track Designation

펠라레오렙-아테졸리주맙, 항문암에 유망한 결과 보여

Pelareorep-atezolizumab shows promising results in anal cancer

Oncolytics Biotech plans to shift incorporation from Canada to Nevada

Oncolytics Biotech files patent application to extend pelareorep protection

Oncolytics Biotech expands GI cancer advisory board with three experts

Oncolytics reports 33% response rate in hard-to-treat colorectal cancer

Oncolytics Biotech reschedules shareholder vote on U.S. domicile move